StreetInsider.com News Articles

BofA starts bullish Alvotech coverage on biosimilar launch cycle

Mon, 24 Aug 2026 06:14:19 -0400

Investing.com -- BofA Securities initiated coverage of Alvotech S.A. with a “buy” rating and a $7 price objective, versus the stock’s $4.43 price as of Monday, after the FDA’s closure of its inspection of the company’s Reykjavik manufacturing facility removed a key regulatory overhang and as the biosimilar developer enters what BofA called its most meaningful launch cycle since inception.

Shares of the company were up 2.7% in pre-open trade.

BofA’s price objective is based on a discounted cash flow analysis assuming a 10% discount rate and a 1% terminal growth rate.

The brokerage’s model projects 2026 earnings

BofA Securities Starts Alvotech SA (ALVO) at Buy

Mon, 24 Aug 2026 05:16:47 -0400

BofA Securities analyst Jason Gerberry initiates coverage on Alvotech SA (NASDAQ: ALVO) with a Buy rating and a price target of $7.00.

The analyst comments "We initiate coverage of Alvotech with a Buy rating and $7 PO. We see an attractive risk/reward as Alvotech’s multi-year investment in an integrated biosimilar development and manufacturing platform begins to translate into a higher-quality commercial growth story. While recent investor sentiment has been weighed down by regulatory uncertainty surrounding the Reykjavik manufacturing facility, the FDA’s closure of the inspection removes a key overhang and clears the path toward new approvals. Having achieved its first full

BofA Securities Starts Alvotech SA (ALVO) at Buy

Mon, 24 Aug 2026 05:16:47 -0400

BofA Securities analyst Jason Gerberry initiates coverage on Alvotech SA (NASDAQ: ALVO) with a Buy rating and a price target of $7.00.

Form 6-K Alvotech For: Aug 21

Fri, 21 Aug 2026 10:37:00 -0400

si-local-file:///var/storage/secattach/20260821/26959606.html

Form 6-K Alvotech For: Aug 21

Fri, 21 Aug 2026 10:37:00 -0400

si-local-file:///var/storage/secattach/20260821/26959606.html

Form 6-K Alvotech For: Jun 30

Wed, 19 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260819/26950584.html

Form 6-K Alvotech For: Jun 30

Wed, 19 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260819/26950584.html

Evercore ISI Starts Alvotech SA (ALVO) at Outperform

Fri, 14 Aug 2026 07:14:31 -0400

Evercore ISI analyst Umer Raffat initiates coverage on Alvotech SA (NASDAQ: ALVO) with a Outperform rating.

The analyst comments "We are expanding our spec pharma coverage universe and with a name which has all the hallmarks: super high leverage, FDA inspection issues, and a path to delevering if biosimilar launches go right. We believe that Alvotech’s recent FDA inspection classification of VAI has majorly derisked the BSUFA dates in 4Q. However, just because ALVO may get approvals on meaningful commercial opportunities like Simponi and Eylea HD etc doesn’t mean they can launch immediately: IP questions will remain."

For an analyst ratings summary

Evercore ISI Starts Alvotech SA (ALVO) at Outperform

Fri, 14 Aug 2026 07:14:31 -0400

Evercore ISI analyst Umer Raffat initiates coverage on Alvotech SA (NASDAQ: ALVO) with a Outperform rating.

For an analyst ratings summary

Form 6-K Alvotech For: Jul 29

Wed, 29 Jul 2026 11:00:00 -0400

si-local-file:///var/storage/secattach/20260729/26832729.html

Form 6-K Alvotech For: Jul 29

Wed, 29 Jul 2026 11:00:00 -0400

si-local-file:///var/storage/secattach/20260729/26832729.html

FDA closes inspection of Alvotech's Iceland facility with VAI rating

Wed, 29 Jul 2026 09:26:28 -0400

Alvotech (NASDAQ: ALVO) announced that the U.S. Food and Drug Administration has closed its inspection of the company's manufacturing facility in Reykjavik, Iceland, with a classification of Voluntary Action Indicated (VAI). The inspection was conducted in May 2026.

A VAI classification indicates that the FDA found objectionable conditions or practices, but the agency is not prepared to take or recommend any administrative or regulatory action.

"This is an important milestone for Alvotech and reflects the significant work our teams have undertaken to further strengthen our quality systems and manufacturing operations," said Lisa Graver, CEO of Alvotech. "We continue to work with the

Alvotech announces successful closure of FDA inspection of manufacturing facility